Cancer cells consume glucose and secrete lactate in culture. It is unknown whether lactate contributes to energy metabolism in living tumors. We previously reported that human non-small-cell lung cancers (NSCLCs) oxidize glucose in the tricarboxylic acid (TCA) cycle. Here, we show that lactate is also a TCA cycle carbon source for NSCLC. In human NSCLC, evidence of lactate utilization was most apparent in tumors with high 18 fluorodeoxyglucose uptake and aggressive oncological behavior. Infusing human NSCLC patients with 13 C-lactate revealed extensive labeling of TCA cycle metabolites. In mice, deleting monocarboxylate transporter-1 (MCT1) from tumor cells eliminated lactate-dependent metabolite labeling, confirming tumor-cell-autonomous lactate uptake. Strikingly, directly comparing lactate and glucose metabolism in vivo indicated that lactate's contribution to the TCA cycle predominates. The data indicate that tumors, including bona fide human NSCLC, can use lactate as a fuel in vivo.
INTRODUCTION
Constitutive glucose uptake is a hallmark of cancer cells and provides energy and biosynthetic material for cancer cell proliferation (Hanahan and Weinberg, 2011) . Accordingly, enhanced expression of glucose transporters and glycolytic enzymes is a common consequence of oncogenic signaling and transcriptional networks (Vander Heiden and DeBerardinis, 2017) . Glucose uptake is also important for metabolic imaging and staging in cancer.
18 fluoro-2-deoxyglucose positron emission tomography (FDG-PET) utilizes the propensity of many solid tumors to take up and retain glucose, providing imaging contrast with adjacent tissue (Fletcher et al., 2008) . The metabolic fates of glucose in FDG-PET-positive tumors and the extent to which other fuels complement glucose utilization in these tumors are areas of active study (Davidson et al., 2016; Fan et al., 2009; Hensley et al., 2016; Mashimo et al., 2014) .
In cultured cancer cells, most glucose carbon is converted to pyruvate via glycolysis, reduced to lactate via lactate dehydrogenase (LDH), and secreted (DeBerardinis et al., 2008) . Disposal of this large carbon pool as lactate serves at least two functions. The NADH-dependent reduction of pyruvate to lactate by LDH recycles the NAD+ reduced to NADH during glycolysis, allowing glycolysis to persist. Excreting lactate through monocarboxylate transporters (MCT; e.g., MCT1, MCT4) eliminates protons arising from the glyceraldehyde 3-phosphate dehydrogenase reaction in glycolysis, thereby maintaining pH homeostasis inside the cell and acidifying the extracellular space. Evidence indicates that lactate in the microenvironment modulates immune cell function and promotes invasion and metastasis, implicating tumor glycolysis and lactate secretion in processes that impact cancer-related mortality (Brand et al., 2016; Rizwan et al., 2013; Xie et al., 2014) .
However, other studies have proposed that tumors use lactate as a fuel, expanding its metabolic functions in cancer. Lactate circulates at levels of 1-2 mM and acts as an interorgan carbon shuttle in mammals (Cori and Cori, 1929) . Some cancer cells use lactate as a respiratory substrate and a lipogenic precursor in culture (Chen et al., 2016) . Blocking lactate uptake with an MCT1 inhibitor reduces respiration and promotes glycolysis in some cancer cell lines and suppresses xenograft growth in mice (Pavlides et al., 2009; Sonveaux et al., 2008) . In mouse models of breast cancer, the growth-promoting effect of stromal cells is impaired by glycolytic inhibition, suggesting that the stroma provides nutritional support to malignant cells by secreting lactate (Bonuccelli et al., 2010; Pavlides et al., 2009 ). Although pyruvate is less abundant than lactate, its circulating levels of 100-200 mM are comparable to other fuels, like leucine. Pyruvate is rapidly taken up by malignant tissue, as indicated by the utility of hyperpolarized [1- 13 C] pyruvate as an imaging probe in human prostate cancer (Nelson et al., 2013) . Alanine, at 200-400 mM in the plasma, is the most abundant amino acid other than glutamine and exchanges with pyruvate via alanine aminotransferase. Some cancer cells require alanine to supply central carbon metabolism (Sousa et al., 2016) . These observations raise the possibility that lactate or the related 3-carbon intermediates, pyruvate and alanine, serve as fuels to complement glucose metabolism in tumors. Recent work has begun to interrogate metabolic pathway flow in human tumors in vivo by providing intravenous 13 C-glucose before or during surgical resection (Faubert and DeBerardinis, 2016) . This approach reveals concomitant glycolysis and glucose oxidation in human non-small-cell lung cancers (NSCLCs) (Fan et al., 2009; Hensley et al., 2016) . Although these tumors are metabolically heterogeneous, a consistent feature is that pyruvate from glycolysis enters the tricarboxylic acid (TCA) cycle through pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC), with both enzymes demonstrating enhanced flow in tumors compared to adjacent benign lung (Hensley et al., 2016; Sellers et al., 2015) . Furthermore, dilution of 13 C labeling between glucose and TCA cycle intermediates extracted from the tumors implies oxidation of alternative fuels in addition to glucose, with lactate as one candidate (Hensley et al., 2016) . Here, we provide the first direct evidence that circulating lactate contributes to central metabolism in human NSCLC in vivo. We also find that lactate's contribution as a respiratory fuel exceeds that of glucose, particularly in tumors growing in the lung.
RESULTS
[U- 13 C]glucose Infusion Reveals Two Major Patterns of 13 
C Enrichment in Human Lung Tumors
We used a previously described protocol to characterize human NSCLC through presurgical imaging; intra-operative infusion of 13 C-labeled nutrients; and postsurgical analysis of metabolic, molecular, and histological features of tumor and adjacent lung (Hensley et al., 2016) . Table S1 contains clinical information from the 35 patients in this cohort, including 9 from our previous study (Hensley et al., 2016) . The tumors included adenocarcinoma (n = 28), squamous cell carcinoma (n = 3), large-cell neuroendocrine carcinoma (n = 1), and carcinoid tumors (n = 3). A sequencing panel to assess oncogenes and tumor suppressor genes commonly mutated in NSCLC, including KRAS, EGFR, PIK3CA, BRAF, STK11, and TP53, confirmed molecular heterogeneity in the cohort (Table S1) .
Thirty of these patients were infused with [U-13 C]glucose. Metabolites extracted from benign lung revealed a progressive reduction in 13 C enrichment downstream of glucose ( Figure 1A ). This pattern suggests dilution of 13 C enrichment by the utilization of unlabeled nutrients. A similar pattern was observed in a subset of tumors, which as a group were practically indistinguishable from metabolite labeling in adjacent lung ( Figure 1A ). However, many tumors displayed a different pattern of 13 C enrichment, in which lactate had excess labeling relative to upstream glycolytic intermediates like 3-phosphoglycerate (3PG) and phosphoenolpyruvate (PEP) ( Figure 1A ). Hereafter, we refer to these two phenotypes as low and high labeling ratios of lactate-to-3PG. Figure S1 and Tables S1 and S2 .
Labeling patterns in adjacent lungs did not differ between tumors with high and low labeling ratios of lactate to 3PG ( Figure S1A ). Complete
13
C isotopologue distributions of all metabolites analyzed in each fragment are in Table S2 .
Our protocol includes ligation of the pulmonary artery prior to surgical resection. Although tumor and adjacent lung tissue continue to receive blood flow from the bronchial artery and collateral vessels, occlusion of the pulmonary artery could, in principle, temporarily impact metabolism and 13 C labeling.
One of the tumors in our cohort could not be resected because it was affixed to the chest wall. In this patient, [U-13 C]glucose was infused intravenously during a needle biopsy of the mass without first occluding blood flow. Metabolites extracted from the resulting 3-mg biopsy had a high lactate-to-3PG labeling ratio similar to the ratio in tumors resected surgically ( Figure 1B ). These findings demonstrate that (1) as previously suggested (Hensley et al., 2016) , the labeling observed in these tumors is unrelated to perturbations of blood flow accompanying pulmonary artery clamping, and (2) needle biopsies contain sufficient tissue for labeling analysis, thereby expanding the clinical contexts in which this type of data may be obtained.
Because the lactate-to-3PG labeling ratio was heterogeneous, we sought to correlate this feature with biological factors that might influence tumor metabolism ( Figures 1C-1I ). EGFRmutant tumors had homogeneous lactate to 3PG labeling ratios similar to those of adjacent lung, whereas the KRAS-mutant group was more heterogeneous and included tumors with ratios far in excess of lung ( Figure 1C) . Similarly, adenocarcinomas with predominantly acinar and nonmucinous histology tended to be homogeneous with low ratios, whereas some tumors with papillary, solid, and large-cell neuroendocrine features had much higher ratios ( Figure 1D ). Histopathology revealed that high-ratio tumors had lower microvessel densities ( Figure 1E ), but there were no differences in Ki67 staining or stromal content (Figures 1F and S1B) .
At the time of infusion, the tumors differed in their degrees of local invasiveness, with some tumors displaying no invasion and others having already spread to regional lymph nodes or the pleural cavity. None of the patients had evidence of distant metastasis, which would have contraindicated resection. The lactate-to-3PG labeling ratio did not correlate with invasion or spread at the time of infusion ( Figure 1G ). Remarkably, however, this ratio did correlate with tumor progression over several years of follow up ( Figure 1H ). Stage I and stage II tumors that recurred in the lung or gave rise to distant metastases had, on average, higher lactate-to-3PG labeling ratios at the time of the original [U- 13 C]infusion and surgery. FDG-PET signal (SUV max , SUV peak , SUV mean ) correlated positively with 13 C enrichment in 3PG, lactate, and the lactate to 3PG labeling ratio, whereas clinical factors like age and smoking were not correlated ( Figure 1I ). Many tumors displayed regional heterogeneity in FDG-PET signal ( Figure 1J ), and in some, but not all, cases, areas of higher signal correlated with higher lactate-to-3PG labeling ratios ( Figure 1J ). Altogether, these data indicate heterogeneity of the lactateto-3PG labeling ratio among human NSCLC tumors and within individual tumors.
Labeled Glycolytic Products in the Blood Contribute to Tumor Metabolism A high lactate-to-3PG labeling ratio is consistent with uptake from the circulation of labeled 3-carbon intermediates distal to 3PG in glycolysis. As previously reported (Hensley et al., 2016) , our infusions produce measurable levels of plasma [U- 13 C] lactate ( Figure 2A ). We also detected plasma [U-
C]pyruvate and [U-
13 C]alanine ( Figure 2A ). Because labeling of plasma lactate and pyruvate exceeded labeling of tumor 3PG, uptake of one or both could contribute to a high-lactate-to-3PG labeling ratio.
We next used metabolic flux analysis (MFA) to explore the contribution of circulating lactate and related metabolites to the tumors. Quantitative MFA in cultured cells usually relies on definitive import and export rates (e.g., glucose import and lactate export) to constrain intracellular fluxes (Buescher et al., 2015) . In vivo, estimating relative fluxes can provide an overview of metabolic activity even if definitive rates cannot be quantified (Hensley et al., 2016) . We constructed a metabolic network to fit 13 C mass isotopologues from plasma glucose and lactate and tissue glucose, lactate, 3PG, and PEP and TCA cycle intermediates ( Figure 2B and Table S3 ). The model incorporates enzymes that convert 4-carbon TCA cycle intermediates to PEP and pyruvate to explain labeling patterns in those 3-carbon intermediates. Such enzymes could include malic enzyme (malate/pyruvate) and PEP carboxykinase (oxaloacetate/PEP). The model does not exclude contributions from the pentose phosphate pathway, which could also produce complex labeling in 3-carbon intermediates. We also examined lactate exchanges between the plasma and tissue. In lungs and tumors with low lactate-to-3PG labeling ratios, these exchanges fit within a narrow range consistent with net lactate export ( Figure 2C ). However, tumors with high lactate-to-3PG labeling ratios were more difficult to fit, with a much wider range of acceptable fluxes, including values consistent with net lactate import ( Figure 2C ). Although this model cannot define quantitative lactate exchange rates or the net direction of flow in vivo, it indicates that tumors with low and high lactate-to-3PG labeling ratios differ with respect to lactate transport, with 13 C features of the latter group consistent with lactate import from plasma. To assess expression of transporters and enzymes involved in taking up and metabolizing lactate, we ranked all tumors from the lowest to highest lactate-to-3PG labeling ratio ( Figure 2D ). Several tumors below and above the median were chosen for western blot analysis. MCT1, MCT4, and LDH isoforms A (LDHA) and B (LDHB) were broadly expressed in these fragments, but the levels of all four proteins tended to be elevated in fragments with high ratios ( Figure 2E ). Figure S2A ). The material was introduced using a bolus followed by a continuous infusion during anesthesia, similar to the [U-the amount of lactate introduced was small relative to the total circulating pool, we monitored for signs of metabolic acidosis. Three patients were modestly acidotic, but in all cases, the acidosis was respiratory in origin, as indicated by elevated partial pressure of CO 2 in arterial blood ( Figure 3A) . The acidosis rapidly resolved with increased mechanical ventilation. Plasma lactate and pyruvate concentrations were not significantly perturbed ( Figure S2B ).
Metabolism of Circulating
These infusions essentially resulted in steady-state labeling of circulating lactate in the 20%-25% range ( Figure 3B ). Pyruvate and alanine were also labeled to appreciable levels, as expected because lactate exchanges with pyruvate and pyruvate exchanges with alanine. Labeling in pyruvate modestly exceeded labeling in lactate. This likely arose from a combination of the infused 13 C-pyruvate, which had a proportionally large effect on the small circulating pyruvate pool, and excess dilution of lactate by unlabeled lactate secreted from the muscle and other tissues. Labeled glucose was also detected, indicating that infused 13 C-lactate was used for gluconeogenesis (Figures 3B and S2C) . In the tumors, comparing labeling in 3PG to labeling in lactate, pyruvate, alanine, and TCA cycle intermediates allowed us to infer whether 13 C entry occurred predominantly through uptake of glucose or of 3-carbon intermediates (Figure 3C) . Inspection of tumor metabolites revealed barely detectable labeling in 3PG and PEP, consistent with the scarce labeling in circulating glucose ( Figure 3D ). However, the tumors contained measurable label in lactate, pyruvate, alanine, and 31  26  53  50  51  13  30  05  07  32  28  29  34  59  33  55  44  03  24  60  02  08  01  09  38 TCA cycle intermediates, most of which were more enriched than 3PG ( Figure 3D ). These findings indicate the propensity of these tumors to take up one or more 3-carbon glycolytic products from the circulation and use them to supply the TCA cycle.
Subcutaneous and Orthotopic NSCLC Xenografts Use Plasma Lactate as a Carbon Source
We next turned to mouse models to more directly assess the role of lactate and related metabolites in live tumors. Mice bearing orthotopic lung or subcutaneous xenografts from H460 NSCLC cells were infused with [U-
13
C]glucose using a protocol analogous to the human studies (Marin-Valencia et al., 2012) . These infusions resulted in labeling of 40% of circulating glucose as [U-
13 C]glucose ( Figure 4A ; isotopologues from mouse experiments are in Table S4 ). Plasma glucose contained m+1, m+2, m+3, and m+5 labeling, in addition to the expected m+6 labeling, indicating that gluconeogenesis from labeled 3-carbon intermediates occurred during the experiment ( Figure S3A ). Plasma lactate, pyruvate, and alanine were also labeled ( Figure 4A ). Healthy lung tissue from these mice displayed a low lactate-to-3PG labeling ratio, similar to human lung (Figures 4B and 4C) . In contrast, the tumors displayed enhanced labeling in lactate, pyruvate, and alanine, relative to 3PG, regardless of the site of the tumor (Figures 4B and 4C) . Subcutaneous xenografts of HCC827 and HCC15 NSCLC cells also displayed high lactateto-3PG labeling ratios after infusion with [U-13 C]glucose ( Figure 4C ). Figure 5F . ****p < 0.0001, ***p < 0.001, **p < 0.01 (one-way ANOVA, Dunnett post hoc versus adjacent lung, n = 5-6 mice per group).
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We next infused mice with [ Figures 4D and 4E ). These infusions did not significantly increase plasma lactate concentrations ( Figure S3B ) and resulted in steady-state plasma lactate enrichments of 23.5 ± 0.01%. HCC827 and HCC15 subcutaneous xenografts also displayed high lactate-to-3PG labeling ratios under this protocol (Figure 4E) . Infusion of either [U- 13 C]pyruvate or [U-
13 C]alanine also labeled tumor metabolites, but in neither case did labeling differ as dramatically from labeling in the lung as for infusions with [
13 C]lactate ( Figures S3C and S3D ). Lactate is much more abundant in plasma than either pyruvate or alanine is, so we focused further effort on documenting its utilization by these tumors. When lactate exchanges with pyruvate via LDH, the proton attached to lactate carbon 2 is transferred to NAD+, producing NADH ( Figure 4F C is retained in pyruvate. We detected enrichment in tumor lactate but, as expected, no labeling in 3PG, pyruvate, or alanine ( Figure 4G ). The TCA cycle intermediate malate was also labeled, presumably through transfer of 2 H from labeled NADH arising from LDH activity ( Figure 4G ). Although this experiment does not rule out uptake of pyruvate and alanine, it confirms that the tumors take up lactate from the circulation.
MCT1-Dependent Lactate Uptake by HCC15 Tumors In Vivo
We explored the mechanism of lactate transport by NSCLC xenografts. Both MCT1 and MCT4 are expressed in human NSCLC ( Figures 2E and S4A ). For functional analysis of MCT1 and MCT4, we used HCC15 cells, an NRAS-and STK11-mutant NSCLC cell line expressing both transporters. We used CRISPR/Cas9 editing to obtain clones of HCC15 lacking either MCT1 or MCT4 ( Figure 5A ). In culture, proliferation persisted after loss of either transporter with no major effect on the doubling time ( Figure S4B ). MCT1 loss resulted in increased oxygen consumption and decreased extracellular acidification, whereas loss of MCT4 had no significant effect on either ( Figures   5B and 5C ). Direct measurements of glucose utilization and lactate secretion revealed a large suppression of glycolysis after MCT1 loss and a modest effect after MCT4 loss ( Figure 5D ), indicating that MCT1 is required for the glycolytic phenotype of HCC15 cells in culture.
To examine the role of MCT1 and MCT4 in vivo, subcutaneous xenografts were established from vector control, MCT1-deficient, and MCT4-deficient HCC15 lines, then tumor-bearing mice were infused with [2-13 C]lactate. MCT1 deficiency reduced labeling in tumor metabolites, nearly eliminating the elevated lactate-to-3PG labeling ratio observed in control tumors (Figure 5E ). Reduced labeling was not an artifact of a large accumulation of unlabeled lactate because the total lactate pool was not significantly altered by MCT1 deficiency ( Figure S4C ). Because the MCT1-deficient tumors had nearly equivalent 13 C enrichment in lactate and 3PG, it is conceivable that labeling in both metabolites arose largely from import of 13 C-glucose labeled via gluconeogenesis. MCT4 deletion only modestly reduced labeling of tumor metabolites ( Figure 5E ). Infusing these tumors with [U-
13 C]glucose also revealed a prominent effect of MCT1 loss, which suppressed the lactate-to-3PG labeling ratio and resulted in a pattern similar to normal lung, whereas MCT4 loss had no effect on labeling from [U-13 C]glucose ( Figures 5F and S4D ). Figure 6A ). Metabolites arising from lactate are labeled as m+1. Short (30 min) infusions were used to limit labeling complexity. Glucose and lactate concentrations in the plasma were not altered ( Figure 6B ). At the end of these infusions, the plasma lactate m+1 and m+3 fractions were equivalent ( Figure 6C ), indicating that some of the glucose-derived labeling in the tumors likely arises from peripheral conversion of glucose to lactate followed by entry of labeled lactate. Thus, the method underestimates lactate's contribution and may See also Figure S3 and Table S4 .
somewhat overestimate the contribution of glycolysis within the tumor. 13 C-lactate was also converted to 13 C-glucose during the infusion, but the glucose m+6 far exceeded the glucose m+1 in the circulation ( Figure 6C ). Labeling of tumor metabolites was normalized to labeling of the precursor (glucose or lactate) in the plasma so that relative contributions of each nutrient could be estimated. Although glucose and lactate made similar contributions to tumor pyruvate, lactate made a much larger relative contribution to the TCA cycle ( Figure 6D ). MCT1-deficient tumors displayed reduced lactate-derived labeling in pyruvate See also Figure S4 and Table S4 . and TCA cycle intermediates, consistent with MCT1's role in lactate import in HCC15-derived tumors ( Figure 6E ). Interestingly, MCT1 deficiency blunted glucose's relative contributions and reduced the absolute enrichment in tumor lactate from either precursor ( Figures 6E and 6F ). This suggests that MCT1 enables lactate uptake from the circulation and also supports glycolytic metabolism in vivo, as it does in culture.
Finally, we compared glucose and lactate metabolism within tumors at two different sites in the same mice, where both tumors were exposed to the same supply of labeled glucose and lactate. H460-derived tumors were grown in the subcutaneous space and orthotopically in the lung, then the mice were coinfused with [U- 13 C]glucose and [3-13 C]lactate. As with the HCC15 tumors, glucose and lactate made comparable contributions to pyruvate, but lactate made a more prominent contribution to the TCA cycle ( Figure 6G ). This difference was much more dramatic in lung tumors, where there was little dilution of label between circulating lactate and TCA cycle intermediates ( Figure 6G ). Thus, NSCLC-derived xenografts consume glucose and lactate concomitantly, with lactate predominating as a carbon source for the TCA cycle. However, the extent to which lactate is used as a respiratory fuel is at least partially related to the anatomic site of the tumor.
DISCUSSION
One of the most fundamental challenges in cancer metabolism is to identify nutrients that fuel production of energy and macromolecular precursors in aggressive tumors. These nutrients and the pathways they supply are candidate targets for cancer imaging and therapy. Several lines of evidence indicate that solid tumors, including NSCLC, display higher levels of glucose metabolism than adjacent benign tissue. The broad utility of FDG-PET indicates that many tumors have an enhanced ability to take up glucose in vivo. Recurrent genomic alterations, including mutations in KRAS, PIK3CA, STK11, TP53, and others enhance glycolytic flux, indicating that reprogrammed glucose metabolism is a shared, cell-autonomous consequence of these mutations (Faubert et al., 2014; Hu et al., 2016; Matoba et al., 2006; Whang et al., 2016; Ying et al., 2012) . Examination of carbon fates by infusing NSCLC patients with 13 C-glucose confirmed both glycolysis and glucose oxidation within the tumors (Fan et al., 2009; Hensley et al., 2016) . However, careful inspection of 13 C labeling strongly suggested that the majority of carbon flow through the TCA cycle in tumors does not arise directly from glucose. The current work presents evidence from both 13 C-glucose and 13 C-lactate infusions that 3-carbon products of glycolysis, including lactate, are consumed by human NSCLC in vivo.
Lactate is an interorgan carbon shuttle, supplying aerobic metabolism and gluconeogenesis (Brooks, 2002) . It is used as a fuel in the heart, brain, and skeletal muscle (Gladden, 2004) . Although most cancer metabolism studies have considered lactate primarily as a waste product secreted as the terminal component of the Warburg effect, recent work has implicated lactate as a potential fuel. In breast cancer cells, estrogenrelated receptor alpha (ERRa) induces expression of genes involved in oxidative metabolism, promotes lactate oxidation, and allows lactate to support cell survival during glucose depletion . Xenografts from breast cancer cell lines take up lactate from the circulation and convert some of it to glutamate, indicating its use as a fuel in these models (Kennedy et al., 2013) .
Human NSCLC exhibits heterogeneity in the extent to which glucose carbon supplies the TCA cycle (Hensley et al., 2016) . We find here that lactate metabolism is also heterogeneous between and within tumors. The lactate-to-3PG labeling ratio varied across our cohort but tracked with several molecular and clinical features. While no histological subtypes displayed exclusively high ratios, we note that tumors with predominantly acinar, nonmucinous, and carcinoid features tended to have low ratios similar to the lung, whereas higher ratios were observed in tumors with papillary, solid, and squamous cell histology. This may indicate that tissue architecture is related to the relative preference or propensity to use lactate as a fuel. A direct assessment of lactate metabolism in mice indicated that the tumor's anatomic location also influences lactate handling. Tumors localized in the lung display a particular predilection to oxidize lactate in the TCA cycle, perhaps because of the high level of perfusion and oxygenation in the lung.
In humans, tumors with high lactate-to-3PG labeling ratios also tended to have high FDG uptake, implying that glucose and lactate are consumed concurrently. High FDG uptake is associated with poor overall survival in NSCLC (Berghmans et al., 2008) . In our cohort, tumors with high lactate-to-3PG labeling ratios were more likely to progress during the study even though the lactate-to-3PG labeling ratio was measured at the time of resection of the primary tumor, in some cases years before recurrence or metastases were observed. Expanding our cohort and extending longitudinal follow-up will allow us to further explore the relationship between metabolic activities and survival. We note that 11 C-lactate has been developed as a PET probe to image cardiac metabolism and perhaps could be used to assess rates of lactate uptake in human NSCLC (Herrero et al., 2007) . It should be emphasized that the lactate-to-3PG labeling ratio in tumors infused with 13 C-glucose is an imperfect surrogate for C-labeling features to better predict fuel preferences. A limitation of the study is that because of the high degree of reversibility of both lactate transporters and LDHs, it is difficult to say whether the transfer of lactate carbon from the plasma into the tumor pyruvate pool represents a net flux. It was not possible in these human lung tumors to cannulate afferent and efferent blood vessels specifically supplying the tumor to calculate rates of glucose extraction and lactate secretion, as Warburg attempted to do in rats (Warburg et al., 1927) . Furthermore, it is likely that some label entering the tumor is carried as pyruvate rather than as lactate, as MCT1 transports both molecules (Garcia et al., 1994; Hong et al., 2016) . It is also clear that the relative importance of MCT1 and MCT4 in lactate transport, the net direction of transport, and the metabolic impact of inhibiting each isoform varies among models and contexts (Doherty et al., 2014; Hong et al., 2016; Marchiq et al., 2015) . However, even considering these caveats, the 2 H-labeling experiment indicates that lactate enters NSCLC xenografts without first being converted to pyruvate, and 13 C labeling of human tumor TCA cycle metabolites after 13 C-lactate infusions demonstrates that a substantial fraction of this carbon arises from circulating lactate. Altogether, the data provide an explanation for the surprisingly low contribution of glucose-derived 13 C to the TCA cycle in human NSCLC (Hensley et al., 2016) . It is interesting that glucose and lactate are consumed concomitantly. It was previously suggested in experimental tumor models that lactate oxidation occurs in well-oxygenated regions as part of symbiotic metabolite exchanges, in which hypoxic cancer cells produce lactate and better-oxygenated cells take up lactate to fuel respiration (Sonveaux et al., 2008) . Although we cannot resolve whether such exchanges occur in human NSCLC, our data indicate that lactate from the circulation is also used as a respiratory substrate. We do not know whether glycolysis and lactate oxidation occur within the same cell, but it is interesting to consider the implications of such a phenotype. Converting pyruvate from glycolysis into lactate resolves the cytosolic redox costs of glycolysis and allows the pathway to persist. Using lactate imported from outside the cell as a respiratory fuel could presumably operate as a parallel pathway to support the energetic and synthetic functions of the TCA cycle. In tumors with high FDG-PET signal, the availability of extracellular lactate as a respiratory fuel might allow glucose to supply other growth-supporting pathways like the pentose phosphate pathway and synthesis of ribose and hexosamines. In culture, cancer cells can use lactate as a carbon source for the TCA cycle and citrate-dependent fatty acid synthesis even when glucose is available (Chen et al., 2016) . In our experiments, co-infusing mice with 13 C-glucose and 13 C-lactate demonstrated equivalent labeling of tumor pyruvate but a striking preference for lactatedependent, rather than glucose-dependent, labeling of TCA cycle intermediates. This implies incomplete mixing of the pyruvate pools generated from 13 C-glucose and lactate. Although several mechanisms could explain this phenomenon, a straightforward one is that mitochondria within these tumor cells contain LDH, thereby channeling lactate carbons into the mitochondrial pyruvate pool destined for the TCA cycle. Such an arrangement could also facilitate NADH generated by LDH to be passed to Complex I of the electron transport chain, maximizing the energy yield. Although cancer cell LDH has generally been viewed as a cytosolic activity, there is evidence for mitochondrial LDH in mammals, including in some cancer cells (Chen et al., 2016; Passarella et al., 2008) .
Analysis of metabolic flux in living human tumors should stimulate a reanalysis of traditional concepts in cancer metabolism, particularly the role of aerobic glycolysis or the Warburg effect. The major components of this pathway, as rendered by Warburg, are the preferential conversion of glucose to lactate, the suppression of glucose oxidation, and the secretion of lactate into the extracellular space. We cannot in human experiments make a full accounting of the quantitative fates of glucose carbon, because we do not know how much lactate and other byproducts of glucose metabolism are secreted from the tumor into the bloodstream. Nevertheless, in human NSCLC, there is no evidence for suppressed glucose oxidation, and the reported data rather suggest activated glucose oxidation relative to adjacent lung (Hensley et al., 2016; Sellers et al., 2015) ; lactate is taken up and seems to be a prominent fuel for the TCA cycle, and TCA cycle activity occurs in regions with high Ki67 content, suggesting that fuel oxidation does not counteract tumor cell proliferation (Hensley et al., 2016) . The availability of multiple fuels for central carbon metabolism, including glucose, lactate, and others, and the marked heterogeneity of fuel choice between and within tumors, will make it challenging to develop universal therapies based on targeting single fuels feeding core pathways like the TCA cycle.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Animal Studies
All procedures were approved by UT Southwestern's Animal Care and Use Committee in accordance with the Guide for the Care and Use of Laboratory Animals. Healthy male and female Ncr nude mice were xenografted at approximately 8-10 weeks of age. All mice were housed in pathogen free conditions prior to use. Prior to the described studies, mice were monitored regularly and determined to be healthy by the veterinary staff.
Cell lines
Cell lines were identified using DNA fingerprinting and confirmed to be mycoplasma free using the e-Myco kit (Boca Scientific). H460, HCC15 and HCC827 cells were provided by J. D. Minna, UT Southwestern. Notable information about these cell lines included the following: H460: Large cell lung cancer cell line from male donor with mutations in KRAS (Q61H), LKB1 (Q37*) and PIK3CA (E545K). HCC827: Adenocarcinoma cell line from female donor with mutation in EGFR (E746-A750 deletion). HCC15: Squamous cell carcinoma cell line from male donor with mutations in NRAS (C186F), LKB1 (homozygous deletion spanning nucleotides 1 to 1,252 of cDNA sequence) and p53 (D259V). All cells were maintained in RPMI-1640 supplemented with penicillin/streptomycin, L-glutamine (4 mM) and 5% fetal bovine serum (FBS) at 37 C in a humidified atmosphere containing 5% CO 2 and 95% air.
METHOD DETAILS Patient Infusions
On the day of surgery, sterile, pyrogen-free [U-
13
C]glucose (Cambridge Isotope, Isotec) was administered as a bolus of 8g over 10 minutes followed by 4 or 8g/hr infusion through a peripheral intravenous line (PIV). Sterile, pyrogen-free [U- C]lactate (Isotec) was administered as a bolus of 150mmol/kg over 5 minutes followed by a 10mmol/kg continuous infusion through a PIV. Infusions generally proceeded for at least two hours prior to tumor resection. A second PIV in the contralateral arm was used to obtain blood to analyze 13 C enrichment. Standard surgical procedures were followed, with the majority of cases being robotic lobectomies. Based on pre-operative imaging and gross inspection at resection, viable fragments of tumor and lung were sampled. In cases where metabolic heterogeneity was assessed, the resected lobe was oriented anatomically to identify regions of the tumor pre-selected by imaging. Tissue fragments were washed in ice-cold saline and immediately frozen in liquid nitrogen. Tumors were stratified to metabolic groups based on the Lactate to 3PG labeling ratio. Ratios of 1.25 and above were considered 'high', and ratios of 1.24 and below were considered 'low'. The value of 1.25 is one standard deviation above the average Lactate to 3PG labeling ratio in all benign lung samples.
Multi-parametric Magnetic Resonance Imaging (mpMRI)
MRI scans occurred within 5 days before surgery on a 3T dual-transmit Achieva MR scanner (Philips Healthcare, Best, the Netherlands) with a 16-channel SENSE-XL Torso Coil or on a 3T Philips Ingenia scanner with a 28-channel dStream Anterior-Posterior coil (Philips Healthcare, Best, the Netherlands). Coronal and axial T2-weighted half-Fourier single-shot turbo spin-echo images were acquired for anatomic reference to localize the lesion. Dynamic contrast enhanced (DCE) MRI was performed using a 2D or 3D T1-weighted spoiled gradient-echo sequence before, during, and after administration of a bolus of 0.01 mmol/kg gadobutrol (Gadavist; Bayer Healthcare Pharmaceuticals) using a power injector at a rate of 2 cc/sec followed by a 20 cc saline flush at the same rate. DCE images were acquired with free-breathing for at least 4 minutes using the following parameters: TE/TR = 1.14-1.65/2.5-4.5 ms, flip angle = 10o, field of view = 200-300 3 200-300 mm2, in-plane resolution = 0.8-1.7 3 0.8-1.7 mm2, and temporal resolution = 0.5-5.2 s. One or more imaging slices were acquired from the lesion with careful planning to avoid artifacts from the heart and major blood vessels. Tumor volume measurements were based on T2-weighted images by ROI segmentation in an Open-Source DICOM Viewer, Osirix. DCE MRI was analyzed by manually selecting regions of interest (ROIs) in Osirix. Average ROI values were plotted at every available time point through the whole series, and subtracted by the baseline signal. Contrast enhancement curves were generated using Excel Solver to calculate constants of a gamma variate function that satisfy a minimum among all data points of a DCE scan and the points of a gamma variate function. Initial area under the curve measurements were approximated with the trapezoidal rule over the first 120 s post-contrast injection. For the noncontrast CT images that were concurrently acquired for attenuation correction and anatomic correlation with PET images, the parameters were 120 kVp, fixed 200 mAS, 3 mm slice thickness in the head and neck and 5 mm slice thickness in the body, pitch 0.8, rotation time 0.5 s. Standardized uptake values (SUV) were calculated with the formula SUV = maximum tissue activity of FDG / (injected dose of FDG x patient body weight). The patients' FDG-PET/CT data were analyzed using a Syngo.Via station using automated gradient-based segmentation method, and the SUV max, mean, peak, metabolic tumor volume (40% threshold), and total lesion glycolysis (40% threshold) were obtained.
FDG-PET Scans
Metabolic Flux Analysis
Steady-state metabolic fluxes were calculated by 13 C mass isotopologue distributions (MIDs) for glucose, 3-phosphoglycerate, phosphoenolpyruvate, pyruvate, lactate, alanine, citrate, glutamate, malate, aspartate, and glutamine using the INCA software package (http://mfa.vueinnovations.com/), which applies an elementary metabolite unit framework to simulate MIDs. We developed reaction networks describing the stoichiometry and carbon transitions of central carbon metabolism with assumptions that are summarized below. To ensure that a global minimum of fluxes was identified, flux estimations were initiated from random values and repeated a minimum of 50 times. A chi-square test was applied to test goodness-of-fit, and accurate 95% confidence intervals were calculated by assessing the sensitivity of the sum of squared residuals to flux parameter variations. Data Table S3 contains the degrees of freedom and sum-of-squared residuals (SSR) for the best fit model and the lower and upper bounds of 95% confidence intervals for all fluxes. MFA procedures and assumptions 1. 13 CO 2 produced during oxidation reactions is not reincorporated via carboxylation reactions.
2. The metabolites succinate and fumarate are symmetrical and their metabolism through the TCA cycle does not produce a particular orientation. 3. The metabolites pyruvate, acetyl-CoA, citrate, a-ketoglutarate, malate, fumarate, and oxaloacetate are metabolically active in both the cytosol and mitochondria. Malate, citrate and a-ketoglutarate are allowed to freely mix between the compartments. 4. The extraction process homogenizes distinct pools of metabolites existing within distinct compartments. Therefore GC-MS analysis of the isotopic enrichment of these metabolites reflects the mixture of distinct metabolic pools. By employing the INCA platform to perform metabolic flux analysis, it is possible to extract meaningful information from these mixed pools.
To do this, the model employs parameters to account for the mixing of mitochondrial and cytosolic metabolites and the existence of intracellular and extracellular metabolite pools. 5. All values are made relative to citrate synthase (CS), which was set at an arbitrary value of 100.
In order to ensure that the model did not become under-constrained, we only included a small number of carbon sources (plasma glucose, plasma glutamine, and tumor glycogen) and carbon sinks (plasma lactate, CO 2 , and lipogenic AcCoA) in the reaction network. These were hypothesized to be the major routes of carbon input and output based on our prior studies and others reported in the literature. We could not obtain direct measurements of these source/sink fluxes in vivo but were able to use the model to estimate their best-fit values through regression of the isotope labeling measurements. While not all fluxes could be precisely quantified using this approach, we were able to determine relative flux ranges (normalized to CS) that were consistent with the isotope labeling measurements (indicated by the 95% confidence bounds in Table S3 ). This allowed for rigorous statistical comparisons to be made between experimental groups, even when some fluxes in the model were not uniquely determined.
Immunohistochemistry H&E slides were scanned in an Aperio scanoscope and analyzed by Aperio Imagescope software. Slides were stained with MIB-1 or CD31 and quantified. Tumor and stromal content was determined using pancytokeratin AE1/AE3 stain. Positive stain corresponds to tumor and negative stain corresponds to stroma. All histological analyses were conducted by surgical pathologists blinded to the results of the metabolic study. Figure 5F .
Mutation Analysis
